These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 33732262)

  • 1. Immunomodulatory Effects of Histone Deacetylation Inhibitors in Graft-vs.-Host Disease After Allogeneic Stem Cell Transplantation.
    Xu X; Li X; Zhao Y; Huang H
    Front Immunol; 2021; 12():641910. PubMed ID: 33732262
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Role of Co-stimulatory/Co-inhibitory Signals in Graft-vs.-Host Disease.
    Kumar S; Leigh ND; Cao X
    Front Immunol; 2018; 9():3003. PubMed ID: 30627129
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting Histone Deacetylases to Modulate Graft-Versus-Host Disease and Graft-Versus-Leukemia.
    Kim S; Santhanam S; Lim S; Choi J
    Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32560120
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Separating graft-versus-leukemia from graft-versus-host disease in allogeneic hematopoietic stem cell transplantation.
    Li JM; Giver CR; Lu Y; Hossain MS; Akhtari M; Waller EK
    Immunotherapy; 2009 Jul; 1(4):599-621. PubMed ID: 20191089
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective NFAT targeting in T cells ameliorates GvHD while maintaining antitumor activity.
    Vaeth M; Bäuerlein CA; Pusch T; Findeis J; Chopra M; Mottok A; Rosenwald A; Beilhack A; Berberich-Siebelt F
    Proc Natl Acad Sci U S A; 2015 Jan; 112(4):1125-30. PubMed ID: 25583478
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Can graft-versus-leukemia reactivity be dissociated from graft-versus-host disease?
    Sprangers B; Fevery S; Van Wijmeersch B; De Somer L; Waer M; Billiau AD
    Front Biosci; 2007 May; 12():4568-94. PubMed ID: 17485398
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Graft-versus-leukemia and graft-versus-host reactions after donor lymphocyte infusion are initiated by host-type antigen-presenting cells and regulated by regulatory T cells in early and long-term chimeras.
    Xia G; Truitt RL; Johnson BD
    Biol Blood Marrow Transplant; 2006 Apr; 12(4):397-407. PubMed ID: 16545723
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Strategies for Enhancing and Preserving Anti-leukemia Effects Without Aggravating Graft-Versus-Host Disease.
    Chang YJ; Zhao XY; Huang XJ
    Front Immunol; 2018; 9():3041. PubMed ID: 30619371
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Th2 and Tc2 cells in the regulation of GVHD, GVL, and graft rejection: considerations for the allogeneic transplantation therapy of leukemia and lymphoma.
    Fowler DH; Gress RE
    Leuk Lymphoma; 2000 Jul; 38(3-4):221-34. PubMed ID: 10830730
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Memory T cells: A helpful guard for allogeneic hematopoietic stem cell transplantation without causing graft-versus-host disease.
    Huang W; Chao NJ
    Hematol Oncol Stem Cell Ther; 2017 Dec; 10(4):211-219. PubMed ID: 28636890
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epigenomics in hematopoietic transplantation: novel treatment strategies.
    Engel N; Rank A
    Epigenomics; 2011 Oct; 3(5):611-23. PubMed ID: 22126249
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ex vivo fludarabine exposure inhibits graft-versus-host activity of allogeneic T cells while preserving graft-versus-leukemia effects.
    Giver CR; Montes RO; Mittelstaedt S; Li JM; Jaye DL; Lonial S; Boyer MW; Waller EK
    Biol Blood Marrow Transplant; 2003 Oct; 9(10):616-32. PubMed ID: 14569558
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Target antigens for graft-versus-host disease (GVHD) and graft-versus-leukemia/tumor (GVL/T)].
    Tanaka J
    Nihon Rinsho; 2003 Sep; 61(9):1512-9. PubMed ID: 14515717
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Graft vs autoimmunity following allogeneic non-myeloablative blood stem cell transplantation in a patient with chronic myelogenous leukemia and severe systemic psoriasis and psoriatic polyarthritis.
    Slavin S; Nagler A; Varadi G; Or R
    Exp Hematol; 2000 Jul; 28(7):853-7. PubMed ID: 10907647
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stem cell mobilization with G-CSF analogs: a rational approach to separate GVHD and GVL?
    Morris ES; MacDonald KP; Hill GR
    Blood; 2006 May; 107(9):3430-5. PubMed ID: 16380448
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD4
    Mancusi A; Piccinelli S; Velardi A; Pierini A
    Front Immunol; 2019; 10():2901. PubMed ID: 31921162
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Donor T cells administered over HLA class II barriers mediate antitumor immunity without broad off-target toxicity in a NOD/scid mouse model of acute leukemia.
    Stevanović S; Nijmeijer BA; van Schie ML; Salvatori DC; Maas S; Griffioen M; Falkenburg JH
    Biol Blood Marrow Transplant; 2013 Jun; 19(6):867-75. PubMed ID: 23500532
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The potential role of γδ T cells after allogeneic HCT for leukemia.
    Handgretinger R; Schilbach K
    Blood; 2018 Mar; 131(10):1063-1072. PubMed ID: 29358176
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Collateral damage of nonhematopoietic tissue by hematopoiesis-specific T cells results in graft-versus-host disease during an ongoing profound graft-versus-leukemia reaction.
    van der Zouwen B; Kruisselbrink AB; Frederik Falkenburg JH; Jedema I
    Biol Blood Marrow Transplant; 2014 Jun; 20(6):760-9. PubMed ID: 24607556
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preimplantation factor reduces graft-versus-host disease by regulating immune response and lowering oxidative stress (murine model).
    Azar Y; Shainer R; Almogi-Hazan O; Bringer R; Compton SR; Paidas MJ; Barnea ER; Or R
    Biol Blood Marrow Transplant; 2013 Apr; 19(4):519-28. PubMed ID: 23266739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.